After careful consideration of the ongoing spread of COVID-19 (coronavirus), the Alliance for Regenerative Medicine (ARM) leadership has regrettably decided to cancel the 2020 Cell and Gene Meeting on the Mediterranean, an annual meeting of sector leaders scheduled to draw more than 500 attendees to Barcelona on April 15-17, 2020.
ARM has been closely monitoring developments in the coronavirus outbreak and recommendations from the World Health Organization (WHO), the U.S. Centers for Disease Control and Prevention (CDC), the European Centre for Disease Prevention and Control (ECDC), and relevant regional European public health authorities. Given the global nature of this meeting, as well as the escalating international public health challenge presented by the coronavirus, ARM feels that cancellation is in the best interest of ARM members, meeting attendees, and staff. ARM will be reaching out to meeting attendees with additional information.
ARM remains committed to its role as the convener and voice of the cell, gene, and tissue-based therapeutic sector globally, and to providing our members with access to the rewarding experience and perspective gained from discussions with thought leaders, policymakers, and industry experts. Additional information on ARM events is available online.
For more information, please visit www.meetingonthemed.com.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. Founded in 2009, ARM works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its 350+ member organizations worldwide. ARM represents the interests of therapeutic developers, academic research institutions, major medical centers, investors, and patient groups that comprise the broader regenerative medicine community and is the prominent international advocacy organization in this field.
ARM has 70+ members across 15 countries in Europe. ARM aims to work closely with European stakeholders, leveraging its membership to create a supportive commercial and regulatory environment to create better conditions for the development and commercialization of ATMPs in Europe; develop strong stakeholder support around proposed solutions to improve patient access to ATMPs; promote clear, predictable and efficient regulatory framework across Europe; and promote international convergence of key regulations and guidance. For more information, visit alliancerm.org
